NYMC Faculty Publications
Anticoagulation in Pulmonary Arterial Hypertension: Do We Know the Answer?
The shear stress and hypoxia in the pulmonary artery in patients with pulmonary arterial hypertension(PAH) causes endothelial dysfunction, smooth muscle proliferation and activation of thrombotic pathways leading to in situ thrombosis. Targeting the thrombotic pathways is a proposed mechanism to slow disease progression and improve survival. Over the years, the survival in patients with PAH has improved due to multiple factors with the increased use of anticoagulation as one of them. Both European Respiratory Society/European Society of Cardiology and American College of Cardiology/American Heart Association guidelines make grade II recommendations for using anticoagulation in PAH. The guidelines are based on weak observational studies with high risk of bias which have only studied warfarin as the choice of anticoagulation. In this article, we review the pathophysiology, rationale and the current literature investigating the role of anticoagulation in PAH.
Rawal, H., Suman, A., Bhoite, R. R., Kanwal, A., Young, R. K., Aronow, W. S., Lavie, C., & Ghosh, R. K. (2021). Anticoagulation in Pulmonary Arterial Hypertension: Do We Know the Answer?. Current Problems in Cardiology, 46 (3), 100738-100738. https://doi.org/10.1016/j.cpcardiol.2020.100738